دورية أكاديمية
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
| العنوان: | Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. |
|---|---|
| المؤلفون: | Patruno C; Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy., Napolitano M; Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy., Argenziano G; Dermatology Unit, University of Campania, Naples, Italy., Peris K; Dermatology, University of the Sacred Heart, Rome, Italy.; Fondazione Policlinico Universitario A.Gemelli, IRCCS, Rome, Italy., Ortoncelli M; Dermatology Clinic, University of Turin, Turin, Italy., Girolomoni G; Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy., Offidani A; Dermatology Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy., Ferrucci SM; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy., Amoruso GF; AO Cosenza, UOC Dermatologia, Cosenza, Italy., Rossi M; UO Dermatologia, ASST Spedali Civili di Brescia, Brescia, Italy., Stingeni L; Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy., Malara G; Struttura Complessa di Dermatologia, Grande Ospedale Metropolitano 'Bianchi Melacrino Morelli', Reggio Calabria, Italy., Grieco T; Dermatology Unit, Sapienza University of Rome, Rome, Italy., Foti C; Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy., Gattoni M; Dermatologic Department, S. Andrea Hospital Vercelli, Vercelli, Italy., Loi C; Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Iannone M; Department of Dermatology, University of Pisa, Pisa, Italy., Talamonti M; Dermatology Unit, Policlinico Tor Vergata, Department of Systemic Medicine, Tor Vergata University of Rome, Rome, Italy., Stinco G; Department of Medicine, Institute of Dermatology, University of Udine, Udine, Italy., Rongioletti F; Unit of Dermatology, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy., Pigatto PD; Department of Medical, Surgical and Odontoiatric Science, IRCCS Ospedale Ortopedico Galeazzi, Milano, Italy., Cristaudo A; San Gallicano Dermatologic Institute IRCCS, Rome, Italy., Nettis E; Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy., Corazza M; Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy., Guarneri F; Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Messina, Italy., Amerio P; Dermatologic Clinic, SS. Annunziata Hospital, Chieti, Italy., Esposito M; Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Belloni Fortina A; Unit of Dermatology, Department of Medicine DIMED, University of Padua, Padua, Italy., Potenza C; Dermatology Unit 'Daniele Innocenzi', Department of MEDICO-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Fiorini Hospital, Polo Pontino, Terracina, Italy., Fabbrocini G; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy. |
| مؤلفون مشاركون: | DADE - Dupilumab for Atopic Dermatitis of the Elderly study group |
| المصدر: | Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Apr; Vol. 35 (4), pp. 958-964. Date of Electronic Publication: 2021 Jan 19. |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: Amsterdam ; New York : Elsevier Science Publishers, c1992- |
| مواضيع طبية MeSH: | Dermatitis, Atopic*/drug therapy , Eczema*, Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Humanized ; Humans ; Middle Aged ; Retrospective Studies ; Severity of Illness Index ; Young Adult |
| مستخلص: | Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly. (© 2020 European Academy of Dermatology and Venereology.) |
| References: | Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol 2020; 182: 47-54. Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol 2011; 25: 12-18. Chello C, Carnicelli G, Sernicola A et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. Int J Dermatol 2020; 59: 716-721. Napolitano M, Fabbrocini G, Scalvenzi M, Blasio C, Stingeni L, Patruno C. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. Clin Exp Dermatol 2020; 45: 888-890. Ramos-e-Silva M, Boza JC, Cestari TF. Effects of age (neonates and elderly) on skin barrier function. Clin Dermatol 2012; 30: 274-276. Bieber T, D'Erme AM, Akdis CA et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol 2017; 139: S58-S64. Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology. Geriatr Gerontol Int 2016; 16: 75-86. Patruno C, Fabbrocini G, Napolitano M. Clinical phenotypes of atopic dermatitis of the adult. G Ital Dermatol Venereol 2020. https://doi.org/10.23736/S0392-0488.20.06532-3 [Epub ahead of print]. Calzavara Pinton P, Cristaudo A, Foti C et al. Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA). G Ital Dermatol Venereol 2018; 153: 133-145. Damiani G, Calzavara-Pinton P, Stingeni L et al. Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther 2019; 32: e13121. Fargnoli MC, Esposito M, Ferrucci S et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat 2019; 1-7. [Epub ahead of print]. De Bruin-Weller M, Thaçi D, Smith CH et al. Dupilumab with concomitant topical corticosteroids in adult patients with AD who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178: 1083-1101. Tanei R, Hasegawa Y, Sawabe M. Abundant immunoglobulin E positive cells in skin lesions support an allergic etiology of atopic dermatitis in the elderly. J Eur Acad Dermatol Venereol 2013; 27: 952-960. Tanei R. Atopic dermatitis in the elderly. Inflamm Allergy Drug Targets 2009; 8: 3984-4404. Megna M, Patruno C, Balato A et al. An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease. Arch Dermatol Res 2017; 309: 443-452. Nettis E, Pellacani G et al. A multicentric study on prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis. J Investig Allergol Clin Immunol 2020; 30: 448-450. Silverberg JI, Vakharia PP, Chopra R, Sacotte R, Patel N, Immaneni S et al. Phenotypical differences of childhood- and adult-onset atopic dermatitis. J Allergy Clin Immunol Pract 2018; 6: 1306-1312. Son JH, Chung BY, Kim HO, Park CW. Clinical features of atopic dermatitis in adults are different according to onset. J Korean Med Sci 2017; 32: 1360-1366. Ozkaya E. Adult-onset atopic dermatitis. J Am Acad Dermatol 2005; 52: 579-582. Kanwar AJ, Narang T. Adult onset atopic dermatitis: under-recognized or under-reported? Indian Dermatol Online J 2013; 4: 167-171. Noda S, Suárez-Fariñas M, Ungar B et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol 2015; 136: 1254-1264. Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in AD. N Engl J Med 2016; 375: 2335-2348. Blauvelt A, de Bruin-Weller M, Gooderham M et al. Long-term management of moderate-to-severe AD with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 2017; 389: 2287-2303. https//www.ema.europa.eu/documents/product-information/dupixent-epar-product-information_en.pdf (last accessed: 20 October 2020). Fargnoli MC, Esposito M, Ferrucci S et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat 2020; 1-4. Olesen CM, Holm JG, Nørreslet LB et al. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral center. J Eur Acad Dermatol Venereol 2019; 33: 1562-1568. Ribero S, Giura MT, Viola R et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience. J Eur Acad Dermatol Venereol 2020; 34: e380-e383. Faiz S, Giovannelli J, Podevin C et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019; 81: 143-151. Igelman SJ, Na C, Simpson EL. Alcohol-induced facial flushing in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep 2020; 6: 139-140. |
| فهرسة مساهمة: | Investigator: L Angileri; T Bianchelli; A Borghi; C Buligan; G Calabrese; P Calzavara Pinton; F Caroppo; C Chello; G Dal Bello; G Damiani; MC Fargnoli; M Ferrillo; M Galluzzo; N Gori; G Gualdi; K Hansel; L Macchia; M Mariano; SP Nisticò; G Pertusi; V Piras; E Provenzano; GM Ravaioli; S Ribero; M Romanelli; P Romita; E Tolino; C Trifirò |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 420K487FSG (dupilumab) |
| تواريخ الأحداث: | Date Created: 20201217 Date Completed: 20210514 Latest Revision: 20210514 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1111/jdv.17094 |
| PMID: | 33332697 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1468-3083 |
|---|---|
| DOI: | 10.1111/jdv.17094 |